Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Patterns of deregulation of insulin growth factor signalling pathway in paediatric and adult gastrointestinal stromal tumours.

Italiano A, Chen J, Zhang L, Hajdu M, Singer S, DeMatteo RP, Antonescu CR.

Eur J Cancer. 2012 Nov;48(17):3215-22. doi: 10.1016/j.ejca.2012.05.021. Epub 2012 Jul 4.

2.

Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA.

Beadling C, Patterson J, Justusson E, Nelson D, Pantaleo MA, Hornick JL, Chacón M, Corless CL, Heinrich MC.

Cancer Med. 2013 Feb;2(1):21-31. doi: 10.1002/cam4.57. Epub 2013 Feb 3.

3.

Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors.

Belinsky MG, Rink L, Flieder DB, Jahromi MS, Schiffman JD, Godwin AK, Mehren Mv.

Genes Chromosomes Cancer. 2013 Feb;52(2):214-24. doi: 10.1002/gcc.22023. Epub 2012 Oct 29.

4.
5.

Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors.

Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, Testa JR, Eisenberg B, von Mehren M, Godwin AK.

Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8387-92. doi: 10.1073/pnas.0803383105. Epub 2008 Jun 11.

6.

Insulin-like Growth Factor (IGF) system and gastrointestinal stromal tumours (GIST): present and future.

Nannini M, Biasco G, Astolfi A, Urbini M, Pantaleo MA.

Histol Histopathol. 2014 Feb;29(2):167-75. doi: 10.14670/HH-29.167. Epub 2013 Oct 16. Review.

PMID:
24129766
7.

Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target.

Pantaleo MA, Astolfi A, Di Battista M, Heinrich MC, Paterini P, Scotlandi K, Santini D, Catena F, Manara MC, Nannini M, Maleddu A, Saponara M, Lolli C, Formica S, Biasco G.

Int J Cancer. 2009 Dec 15;125(12):2991-4. doi: 10.1002/ijc.24595.

8.

Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.

Hayashi Y, Bardsley MR, Toyomasu Y, Milosavljevic S, Gajdos GB, Choi KM, Reid-Lombardo KM, Kendrick ML, Bingener-Casey J, Tang CM, Sicklick JK, Gibbons SJ, Farrugia G, Taguchi T, Gupta A, Rubin BP, Fletcher JA, Ramachandran A, Ordog T.

Gastroenterology. 2015 Aug;149(2):420-32.e16. doi: 10.1053/j.gastro.2015.04.006. Epub 2015 Apr 9.

9.

Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification.

Janeway KA, Zhu MJ, Barretina J, Perez-Atayde A, Demetri GD, Fletcher JA.

Int J Cancer. 2010 Dec 1;127(11):2718-22. doi: 10.1002/ijc.25247.

10.

Expression of IGF-1 receptor in KIT/PDGF receptor-α wild-type gastrointestinal stromal tumors with succinate dehydrogenase complex dysfunction.

Nannini M, Astolfi A, Paterini P, Urbini M, Santini D, Catena F, Indio V, Casadio R, Pinna AD, Biasco G, Pantaleo MA.

Future Oncol. 2013 Jan;9(1):121-6. doi: 10.2217/fon.12.170.

PMID:
23252569
11.

Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients.

Braconi C, Bracci R, Bearzi I, Bianchi F, Sabato S, Mandolesi A, Belvederesi L, Cascinu S, Valeri N, Cellerino R.

Ann Oncol. 2008 Jul;19(7):1293-8. doi: 10.1093/annonc/mdn040. Epub 2008 Mar 27.

PMID:
18372285
12.

Involvement of signaling molecules in the prediction of response to imatinib treatment in metastatic GIST patients.

Valadão M, Braggio D, Santos AF, Pimenta-Inada HK, Linhares E, Gonçalves R, Romano S, Vilhena B, Small I, Cubero D, Cruz F, Oliveira AT, Martinho O, Reis RM, Guimarães DP, Ferreira CG.

J Surg Res. 2012 Nov;178(1):288-93. doi: 10.1016/j.jss.2012.03.031. Epub 2012 Apr 5.

PMID:
22516345
13.

Succinate dehydrogenase-deficient GISTs are characterized by IGF1R overexpression.

Chou A, Chen J, Clarkson A, Samra JS, Clifton-Bligh RJ, Hugh TJ, Gill AJ.

Mod Pathol. 2012 Sep;25(9):1307-13. doi: 10.1038/modpathol.2012.77. Epub 2012 May 4.

14.

An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST).

Nannini M, Biasco G, Astolfi A, Pantaleo MA.

J Med Genet. 2013 Oct;50(10):653-61. doi: 10.1136/jmedgenet-2013-101695. Epub 2013 Jul 5. Review.

PMID:
23833252
15.

Molecular characterization of pediatric gastrointestinal stromal tumors.

Agaram NP, Laquaglia MP, Ustun B, Guo T, Wong GC, Socci ND, Maki RG, DeMatteo RP, Besmer P, Antonescu CR.

Clin Cancer Res. 2008 May 15;14(10):3204-15. doi: 10.1158/1078-0432.CCR-07-1984.

16.

An immunohistochemical study of potential diagnostic and therapeutic biomarkers of wild-type gastrointestinal stromal tumours.

Wong NA, Wingate J, Gradhand E.

Histopathology. 2015 Sep;67(3):378-85. doi: 10.1111/his.12667. Epub 2015 Mar 17.

PMID:
25659413
17.

DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors.

Simon S, Grabellus F, Ferrera L, Galietta L, Schwindenhammer B, Mühlenberg T, Taeger G, Eilers G, Treckmann J, Breitenbuecher F, Schuler M, Taguchi T, Fletcher JA, Bauer S.

Cancer Res. 2013 Jun 15;73(12):3661-70. doi: 10.1158/0008-5472.CAN-12-3839. Epub 2013 Apr 10.

18.

High expression of the RNA-binding protein RBPMS2 in gastrointestinal stromal tumors.

Hapkova I, Skarda J, Rouleau C, Thys A, Notarnicola C, Janikova M, Bernex F, Rypka M, Vanderwinden JM, Faure S, Vesely J, de Santa Barbara P.

Exp Mol Pathol. 2013 Apr;94(2):314-21. doi: 10.1016/j.yexmp.2012.12.004. Epub 2013 Jan 4.

PMID:
23295309
19.

GSTT1 copy number gain and ZNF overexpression are predictors of poor response to imatinib in gastrointestinal stromal tumors.

Lee EJ, Kang G, Kang SW, Jang KT, Lee J, Park JO, Park CK, Sohn TS, Kim S, Kim KM.

PLoS One. 2013 Oct 4;8(10):e77219. doi: 10.1371/journal.pone.0077219. eCollection 2013.

20.

Expression of insulin-like growth factor 2 in mesenchymal neoplasms.

Steigen SE, Schaeffer DF, West RB, Nielsen TO.

Mod Pathol. 2009 Jul;22(7):914-21. doi: 10.1038/modpathol.2009.48. Epub 2009 May 1.

Supplemental Content

Support Center